In the News

A 3-drug combination of elexacaftor, tezacaftor, and ivacaftor may benefit patients with cystic fibrosis with Phe508del-minimal function genotypes, in whom previous cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimens have been ineffective, according to a study published...

The US Food and Drug Administration (FDA) has approved the first triple combination therapy to treat patients aged 12 years and older with cystic fibrosis who have at least 1 F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent...

Patients with cystic fibrosis (CF) who take ivacaftor appear to have fewer respiratory infections over time than those not taking the drug, according to a study published online in the Annals of the American Thoracic Society.

The study also showed that ivacaftor may also reduce...

Adding new clinical variables to the lung allocation score can help to better identify the sickest patients with cystic fibrosis and chronic obstructive pulmonary disease (COPD) awaiting transplants, according to a study published in the American Journal of Respiratory and Critical Care...

The US Food and Drug Administration (FDA) has expanded the indication for tezacaftor/ivacaftor tablets (Symdeko) for the treatment of paediatric patients aged 6 years and older with cystic fibrosis who have certain genetic mutations.

Last year, the FDA approved tezacaftor/ivacaftor to...

The build-up of abnormally thick mucus and associated inflammation appear to be the initiating cause of lung damage in children with cystic fibrosis (CF), rather than bacterial infections, according to a study published in Science Translational Medicine.

The research suggests that...

Therapeutic and subtherapeutic beta-lactam antibiotic use is associated with different patterns of microbial changes in the lungs of patients with cystic fibrosis, according to a study published in Scientific Reports.

Worsening lung function in patients with cystic fibrosis has...

An antioxidant-enriched vitamin may decrease respiratory exacerbations in people with cystic fibrosis (CF), according to a study published in the American Journal of Respiratory and Critical Care Medicine.

Scott D. Sagel, MD, Children’s Hospital Colorado, Aurora, Colorado, and...

A study published in Thorax has shown that babies with cystic fibrosis (CF) are born weighing less than babies without the condition.

For the study, Daniela Schlüter, PhD, Lancaster Medical School, Lancaster, United Kingdom, and colleagues used data on 2.2 million babies in Denmark...

The majority of patients with cystic fibrosis may not achieve blood concentrations of antibiotics sufficiently high enough to effectively fight bacteria responsible for pulmonary exacerbations, leading to worsening pulmonary function, according to a study published in the Journal of Pediatric...

Pages